A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1

One of the most relevant targets in the field of novel targeted anticancer therapy is the family of receptors to fibroblast growth factor receptors (FGFRs). FGFR1 is the main representative of the FGFR family. The goal of this clinical trial is to learn if monoclonal anti-FGFR1 antibody (OM-RCA-01) works to treat metastatic cancers expressing FGFR1. It will also learn about the safety of drug OM-RCA-01. The main questions it aims to answer are: 1. What medical problems do participants have when receiving drug OM-RCA-01? 2. What dose of the drug should patients receive in the next studies? 3.

Trial Details

NCT ID
NCT07292168
Phase
PHASE1 / PHASE2
Sponsor
Kidney Cancer Research Bureau
Status
RECRUITING
Cancer Type
Small Cell (SCLC) Lung Cancer
Interventions
  • humanized monoclonal anti-FGFR1 antibody OM-RCA-01
Locations (sample)
  • Kazan', Russia|55.78874,49.12214
  • Krasnoyarsk, Russia|56.03742,92.93136
  • Moscow, Russia|55.75204,37.61781
  • Saint Petersburg, Russia|59.93863,30.31413
  • Ufa, Russia|54.74306,55.96779

Key Eligibility Criteria

  • Signed and dated Informed Consent Form confirming voluntary participation in the study.
  • Age ≥ 18 years at the time of consent.
  • Body weight ≥ 50 kg.
  • Histologically confirmed metastatic solid tumors:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Small Cell (SCLC) Lung Cancer Trials on Trialify →